MDGL
Madrigal Pharmaceuticals Inc
496.50$
+0.6%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +150.0% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +324.8% | +66.2% | +32.8% | +55.0% | +35.0% | +11.8% | -3.0% | +17.0% | – | |
| – | – | – | – | +12.5% | +566.7% | -61.7% | +4.3% | +0.0% | +4.2% | +12.0% | +0.0% | +0.0% | +0.0% | +346.4% | -8.0% | +0.0% | +0.9% | -2.6% | -21.2% | +9.0% | +9.3% | +0.9% | +2.8% | +10.0% | +6.6% | -3.9% | +1.6% | +7.1% | +5.2% | +18.3% | +278.6% | +238.4% | +60.1% | +31.0% | +100.9% | +99.9% | +34.9% | +9.8% | +49.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +328.7% | +66.4% | +32.9% | +53.5% | +32.1% | +10.2% | -4.1% | +14.0% | – | |
| – | -29.2% | -20.7% | +55.6% | -2.0% | -2.5% | -20.2% | -1.7% | +21.6% | +42.8% | +39.5% | +26.0% | +24.7% | +28.1% | +34.1% | +33.8% | +19.3% | +0.3% | -14.3% | +12.8% | +6.3% | -3.6% | -9.4% | +22.1% | +16.7% | +3.6% | -12.1% | +10.4% | +3.4% | -0.4% | +0.8% | -0.2% | -3.3% | -62.7% | +72.2% | +22.4% | +221.7% | -33.2% | -6.5% | -16.1% | – | |
| – | -64.5% | -24.1% | -4.2% | +20.5% | +22.7% | -22.0% | +45.2% | +88.5% | +9.0% | +2.9% | +23.7% | -33.2% | +6.2% | -8.7% | +22.5% | -2.6% | +11.5% | +17.7% | +40.2% | -18.0% | +41.3% | -17.5% | +21.9% | +3.1% | +19.9% | +11.2% | +10.3% | +54.6% | +68.7% | +73.6% | +30.5% | +2.0% | +173.1% | -42.9% | +5.5% | +18.1% | +0.0% | +28.4% | +7.8% | – | |
| – | -45.0% | -20.9% | +38.8% | +2.3% | +2.6% | -20.4% | +10.7% | +45.0% | +27.6% | +25.4% | +25.3% | +6.6% | +23.9% | +26.9% | +32.4% | +16.8% | +1.3% | -11.0% | +16.5% | +2.3% | +2.3% | -10.9% | +22.0% | +14.4% | +6.1% | -8.2% | +10.4% | +14.0% | +18.9% | +29.8% | +16.1% | -0.1% | -5.4% | +27.1% | +18.3% | +52.7% | -7.0% | +5.9% | +0.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -83.2% | +496.8% | -100.0% | – | – | -100.0% | – | – | – | – | – | – | – | -15.5% | -35.6% | -31.6% | +426.0% | -96.3% | -43.1% | -34.1% | +505.0% | -81.0% | +1,030.4% | +92.6% | +12.0% | +38.9% | +24.2% | +20.8% | +13.3% | -3.3% | -4.7% | +0.6% | -4.9% | -5.8% | -1.0% | +128.3% | +11.4% | -5.8% | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -100.0% | – | – | -376.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +1,030.4% | +92.6% | +12.0% | -46.7% | +282.3% | -103.9% | – | +27.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.